For dose adjustment in patients with obesity, the following PK assumptions have been proposed: 1) the volume of distribution increases for lipophilic drugs but not for hydrophilic molecules; 2) lean body weight serves as a size descriptor and better predicts clearance and volume of distribution; 3) CYP3A4 activity is decreased, and UGTs is increased; 4) glomerular filtration rate is increased. The gene discussed is CYP3A4; the disease is Obesity.